InCarda Therapeutics Revenue and Competitors

Location

$77.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • InCarda Therapeutics's estimated annual revenue is currently $2M per year.(i)
  • InCarda Therapeutics's estimated revenue per employee is $77,500
  • InCarda Therapeutics's total funding is $77.9M.

Employee Data

  • InCarda Therapeutics has 26 Employees.(i)
  • InCarda Therapeutics grew their employee count by -61% last year.

InCarda Therapeutics's People

NameTitleEmail/Phone
1
President and CEOReveal Email/Phone
2
Co-Founder, COO (Consulting)Reveal Email/Phone
3
Chief Technology OfficerReveal Email/Phone
4
Chief Technology Officer and Co-founderReveal Email/Phone
5
Chief Technology Officer and Co-founderReveal Email/Phone
6
VP Clinical OperationsReveal Email/Phone
7
ControllerReveal Email/Phone
8
Contract Clinical Trial ManagerReveal Email/Phone
9
N/AReveal Email/Phone
10
Clinical Research AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2M26-61%$77.9MN/A
Add Company

What Is InCarda Therapeutics?

InCarda Therapeutics is a clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route. The lead product under development is an inhaled therapy to treat a common atrial arrhythmia, paroxysmal atrial fibrillation (PAF).

keywords:N/A

$77.9M

Total Funding

26

Number of Employees

$2M

Revenue (est)

-61%

Employee Growth %

N/A

Valuation

N/A

Accelerator

InCarda Therapeutics News

2022-04-17 - Highlights From the Circulation Family of Journals | Circulation

... Universiteitssingel 50, 6229 ER Maastricht, The Netherlands; or Luiz Belardinelli, MD, InCarda Therapeutics Inc, 39899 Balentine Dr,...

2020-10-21 - InCarda raises $30M to reimagine afib treatment with drug-device combo

Flecainide has been around to treat atrial fibrillation since the '80s, but Grace Colón, CEO of InCarda Therapeutics, thinks it needs a face-lift. Armed with $30 million in venture funding, InCarda hopes to make the drug available as an at-home inhalable treatment for patients in the early stage ...

2019-11-08 - InCarda Therapeutics raises $35 million

InCarda Therapeutics — which is developing an inhaled paroxysmal atrial fibrillation drug — filed an SEC Form D confirming the sale of more than $35 million in equity. The Newark, Calif.–based drug-device combo company sold nearly $35.3 million since the first sale of the offering occurred on O ...

2015-04-28 - InCarda Therapeutics Raises over $5M in Series A Financing

InCarda Therapeutics, Inc., a San Francisco, CA-based biotechnology company focused on the development and commercialization of therapies for acute cardiovascular conditions via the inhalation route, raised over $5m Series A financing. Potential additional tranches can bring to a total of $1.5m ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.2M268%N/A
#2
$3.5M2613%N/A
#3
$2.5M26-21%N/A
#4
$2.6M2663%N/A
#5
$2.2M2624%$2M